Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 3 11Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 66INDUSTRY 22NIH 8NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 13Cisplatin 8Cytarabine 7carfilzomib 5Specimen Handling 5Paclitaxel 5Dexamethasone 5Methotrexate 4Lapatinib 4Gemcitabine 4Fluorouracil 4Docetaxel 4Brachytherapy 4Biopsy 4venetoclax 3pomalidomide 3Temozolomide 3Radiotherapy, Conformal 3Leucovorin 3Irinotecan 3Etoposide 3Cyclophosphamide 3Carboplatin 3neratinib 2merphos 2Vincristine 2Radiation 2Polymerase Chain Reaction 2Oxaliplatin 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × Bortezomib × Clear all
NCT01460420 2017-07-06

EMN-alloRIC

European Myeloma Network B.V.

Phase 1/2 Completed
49 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00516100 2010-01-15

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Aptium Oncology Research Network

Phase 1/2 Unknown
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡